Bone Metabolic Disadvantages of Mifepristone in the Treatment of Endometriosis

Objective To investigate the effect of mifepristone in treating endometriosis on the bone metabolism,and evaluate its safety and clinical practical value.Methods Compared with danazol,we observed the side effects of mifepristone in the treatment of endmetriosis.With the methods of enzyme-linked immunosorbent assay,radioimmuno assay and spectrophotometry,urinary DPD/Cr,serum AKP and BGP were measured before and after mifepristone treating endometriosis for 3 months and the effect on bone metabolism.Results During the 3 months′ treatment,there was no significant difference in patients with pelvic pain symptoms (dysmenorrhea,hypogastic pain and coital pain) in mifepristone group and danazol (P005).There was no significant difference in urinary DPD/cr and serum AKP/BGP before and after using medicine(P005).Conclusion Mifepristone had been used consistently for 3 months,it had no bone metabolic effect,and patients had no the risk of osteoporosis.Mifepristone was used safely.